Search
Jupiter Neurosciences Inc
JUNSAdd to Watchlist
4.750USD
-0.490-9.35%
Close 08-14 16:00（ET）Quotes delayed by 15 min
42.10KMarket Cap
LossP/E TTM
Forecast
Currency: USD Updated: 2026-08-14No earnings forecast score is currently available for Jupiter Neurosciences Inc. The Biotechnology & Medical Research industry's average is 8.10.
Analyst Rating
Based on
1
analysts
Buy
Current Rating
25.000
Target Price
0.00%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
497
Total
6
Median
7
Average
Company name
Ratings
Analysts
Jupiter Neurosciences Inc
JUNS
1
argenx SE
ARGX
28
Beigene Ltd
ONC
28
Ionis Pharmaceuticals Inc
IONS
25
IQVIA Holdings Inc
IQV
24
Kymera Therapeutics Inc
KYMR
23
1
2
3
...
100
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Jupiter Neurosciences Inc's expected revenue for the next quarter?
Jupiter Neurosciences Inc's expected revenue is 602.00K.
How have Jupiter Neurosciences IncJUNS's recent earnings per share performed?
The market expectation was USD -305.94, while Jupiter Neurosciences IncJUNS's earnings per share (EPS) for the previous quarter was USD -0.06. EPS for the next quarter is expected at USD -0.05.
What is the analyst rating for Jupiter Neurosciences Inc?
Based on the ratings of Jupiter Neurosciences Inc's stock from 1 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.